Comparative Pharmacology
Head-to-head clinical analysis: ANUSOL HC versus CAPEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANUSOL HC versus CAPEX.
ANUSOL HC vs CAPEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrocortisone, a corticosteroid, binds to glucocorticoid receptors, inhibiting phospholipase A2 activity and reducing prostaglandin and leukotriene synthesis. It also suppresses cytokine production and inflammatory cell migration, leading to decreased edema, erythema, and pruritus in anorectal tissues.
Corticosteroid with anti-inflammatory, antipruritic, and vasoconstrictive properties.
Apply a thin layer to the affected area rectally 2 to 4 times daily, or after each bowel movement, for up to 7 days. Each application should not exceed 1 gram.
Topical application of a thin film twice daily to affected areas. Not for ophthalmic, oral, or intravaginal use.
None Documented
None Documented
Terminal elimination half-life of hydrocortisone is approximately 1.5-2 hours (range 1-3 h) in adults; clinical effect outlasts half-life due to intracellular receptor-mediated action.
Terminal elimination half-life is approximately 1.5–2 hours. This short half-life supports twice-daily dosing for maintenance of therapeutic levels.
Renal (primarily as metabolites) >80%; fecal ~15%; <2% unchanged in urine due to extensive hepatic metabolism. Biliary excretion is negligible.
Primarily renal (hepatic metabolism to inactive metabolites; <1% excreted unchanged in urine). Fecal elimination accounts for <5%.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid